138 related articles for article (PubMed ID: 17354648)
1. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
Biswas S; Swift M; Field HJ
Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
[TBL] [Abstract][Full Text] [Related]
2. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1.
Biswas S; Smith C; Field HJ
J Antimicrob Chemother; 2007 Aug; 60(2):274-9. PubMed ID: 17550887
[TBL] [Abstract][Full Text] [Related]
3. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
[TBL] [Abstract][Full Text] [Related]
4. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
[TBL] [Abstract][Full Text] [Related]
5. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
Biswas S; Jennens L; Field HJ
Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
[TBL] [Abstract][Full Text] [Related]
6. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
[TBL] [Abstract][Full Text] [Related]
8. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir.
Field HJ; Huang ML; Lay EM; Mickleburgh I; Zimmermann H; Birkmann A
Antiviral Res; 2013 Nov; 100(2):297-9. PubMed ID: 24021190
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
[TBL] [Abstract][Full Text] [Related]
10. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
[TBL] [Abstract][Full Text] [Related]
11. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
Wozniak MA; Frost AL; Itzhaki RF
Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
[TBL] [Abstract][Full Text] [Related]
12. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
13. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
[TBL] [Abstract][Full Text] [Related]
14. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
[TBL] [Abstract][Full Text] [Related]
16. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
Kleymann G
Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations.
Biswas S; Field HJ
Antivir Chem Chemother; 2008; 19(1):1-6. PubMed ID: 18610552
[TBL] [Abstract][Full Text] [Related]
18. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease.
Baumeister J; Fischer R; Eckenberg P; Henninger K; Ruebsamen-Waigmann H; Kleymann G
Antivir Chem Chemother; 2007; 18(1):35-48. PubMed ID: 17354650
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
[TBL] [Abstract][Full Text] [Related]
20. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
